NCT04829305View on ClinicalTrials.gov

A Trial of SHR2285 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

September 6, 2021

Study Completion Date

September 6, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

SHR2285

SHR2285 is a selective inhibition of human FXIa small molecule compound.

Trial Locations (1)

6009

Linear Clinical research, Perth

All Listed Sponsors

lead

Atridia Pty Ltd.

INDUSTRY